These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18620457)

  • 1. Waiting for reimbursement of new medicines in Canada: it's time for a rethink.
    Skinner BJ
    Pharmacoeconomics; 2008; 26(8):629-32. PubMed ID: 18620457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.
    Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR
    Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program.
    Després F; Perreault S; Lalonde L; Forget A; Kettani FZ; Blais L
    Can J Cardiol; 2014 May; 30(5):560-7. PubMed ID: 24613090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the adherence and persistence to inhaled corticosteroids among adult patients with public and private drug insurance plans.
    Cyr MC; Beauchense MF; Lemiere C; Blais L
    J Popul Ther Clin Pharmacol; 2013; 20(1):e26-41. PubMed ID: 23392860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not All Insurance Is Equal: Differential Treatment and Health Outcomes by Insurance Coverage Among Nonelderly Adult Patients With Heart Attack.
    Niedzwiecki MJ; Hsia RY; Shen YC
    J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29871858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 8. [Is the physician the insurance broker for his patients?].
    Wienke A; Sailer R
    Laryngorhinootologie; 2013 Dec; 92(12):834-5. PubMed ID: 24285207
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of health insurance in financing vaccinations for children and adolescents in the United States.
    Shen AK; Hunsaker J; Gazmararian JA; Lindley MC; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S522-31. PubMed ID: 19948584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regulators in access to anticancer drugs in Canada].
    Côté A; Keating B; Parent M; Simard G
    Sante Publique; 2015; 27(4):515-27. PubMed ID: 26751926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea.
    Shih YR; Liao KH; Chen YH; Lin FJ; Hsiao FY
    Clin Transl Sci; 2020 Sep; 13(5):916-922. PubMed ID: 32166908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug coverage insurance as a novel element of private health insurance in Poland.
    Czerw A; Religioni U
    Acta Pol Pharm; 2013; 70(4):763-7. PubMed ID: 23923401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of financial barriers to pediatric cochlear implantation: impact of socioeconomic status on access and outcomes.
    Chang DT; Ko AB; Murray GS; Arnold JE; Megerian CA
    Arch Otolaryngol Head Neck Surg; 2010 Jul; 136(7):648-57. PubMed ID: 20644058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The illegality of private health care in Canada.
    Flood CM; Archibald T
    CMAJ; 2001 Mar; 164(6):825-30. PubMed ID: 11276552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Private, individual drug coverage in the current Medicare market.
    Boccuti C; Moon M
    Policy Brief Commonw Fund; 2003 Oct; (679):1-10. PubMed ID: 14562796
    [No Abstract]   [Full Text] [Related]  

  • 20. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.